A-01
Registration at the Conference Venue
Tuesday 14:00-17:00 |
A-02
Opening Ceremony, Welcome Reception
Tuesday 19:00-22:00 |
B-01
Registration at the Conference
Wednesday 8:00-8:40 |
B-05 Lorenzo Contento
Improving simulations by learning the true random effects' distribution from a population using generative machine learning
Wednesday 9:00-9:20 |
B-06 Sam Richardson
Automating Population Pharmacokinetic Model Development using Machine Learning
Wednesday 9:20-9:40 |
B-07 Gilbert Koch
Learning from machine learning - how to deduce a mechanism-based pharmacometrics model for serum creatinine in preterm neonates from neural ordinary differential equations
Wednesday 9:40-10:00 |
B-08 Ercan Suekuer
PMx-AI Bot: Changing the way of traditional Pharmacometrics work with AI Bots
Wednesday 10:00-10:20 |
B-09
Coffee Break, Poster and Software session I
Wednesday 10:20-11:50 |
B-11 Paolo Denti
Handling within-subject/between-occasion variability in longitudinal data: Common Challenges and Practical Solutions
Wednesday 11:50-12:30 |
B-12
Lunch
Wednesday 12:30-14:00 |
B-14 Pascal Chanu
A disease model for Multiple Myeloma developed using Real World Data and validated on Phase 3 clinical trials
Wednesday 14:00-14:20 |
B-14 Samer Mouksassi
Streamlining Clinical Development of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Pediatric Chronic Kidney Disease Patients by Integration of Clinical Trial and Real-World Data
Wednesday 14:20-14:40 |
B-15 Luca Marzano
Overcoming the discrepancies between clinical trials and real-world data of small cell lung cancer chemotherapy. A data-driven approach to learn across real-world evidence studies
Wednesday 14:40-15:00 |
B-16 Aole Zheng
A Novel Approach Using Pharmacometrics/Pharmacoeconomic (PMPE) Model for Cost-effectiveness Analysis of Tacrolimus-Diltiazem Combination in Liver Transplant Patients: Evidence from Real-world Clinical Data
Wednesday 15:00-15:20 |
B-17
Coffee Break, Poster and Software session II
Wednesday 15:20-16:50 |
B-18 Alzahra Hamdan
Integrated modeling of digital-motor outcomes and clinical outcome assessments using IRT: a framework for developing better outcomes for clinical trials in rare neurological diseases
Wednesday 16:50-17:10 |
B-20 Marina Savelieva
Virtual Patient Cohorts using Modeling and Simulation to support drug development in rare diseases
Wednesday 17:10-17:30 |
C-02 Wendy Chu
Optimizing dosing strategies for post-kala-azar dermal leishmaniasis: a geographical comparison of systemic and skin pharmacokinetics and pharmacodynamics of antileishmanial drugs
Thursday 8:30-8:55 |
C-03 Selma El Messaoudi
Mechanistic modeling of the long-term dynamics of viral markers to predict the outcome of combination therapy in chronic HBV and HDV infections
Thursday 8:55-9:20 |
C-04 Julie Dudasova
Logistic regression-based approach to assess heterogeneity in vaccine efficacy using immunogenicity measurements in phase 3 clinical trials
Thursday 9:20-9:45 |
C-05
Presentation Lewis Sheiner Student Session Awards
Thursday 9:45-9:50 |
C-06
Cofee break, Poster and Software session III
Thursday 9:50-11:20 |
C-08 Rik Schoemaker
Quantification of the analgesic effect of intranasal coadministration of ketamine and sufentanil in adults to support the development of a pain relief treatment (CT001) in children
Thursday 11:20-11:40 |
C-09 Sandrine Boulet
Bayesian framework for multi-source data integration - application to Human extrapolation from preclinical studies
Thursday 11:40-12:00 |
C-10 Laila Nassar
Pharmacokinetics During Hemodialysis and Hemodiafiltration: Dialysis Clearance is more important than Dialysis Efficiency - Application to Amikacin
Thursday 12:00-12:20 |
C-11 Davide Bindellini
From physiology to disease: A quantitative framework for system-disease-drug interaction in cortisol replacement therapy
Thursday 12:20-12:40 |
C-12
Lunch
Thursday 12:40-14:10 |
C-14 Javier Sanchez Fernandez
Optimizing Molecule Design for Bispecific Antibodies in Immuno-Oncology: A Case Study with FAP-4-1BBL
Thursday 14:10-14:30 |
C-15 Robin Haid
Transforming the discovery of targeted protein degraders: the translational power of predictive PK/PD modeling
Thursday 14:30-14:50 |
C-17
Coffee Break, Poster and Software session IV
Thursday 15:00-16:30 |
C-19 Auriane Gabaut
High-dimension Mechanistic Model Building using LASSO Approaches : Application to Ebola Vaccination
Thursday 16:30-16:50 |
C-20 Nelleke Snelder
Time-varying covariates, mediation analysis and overadjustment bias in PK/PD modelling
Thursday 16:50-17:10 |
C-21 Mohamed Tarek
Make models great again by optimally restricting parameters to make non-identifiable models provably identifiable
Thursday 17:10-17:30 |
C-22
Gala Dinner
Thursday 20:00-01:00 |
D-02 Lorenzo Dasti
A Quantitative System Pharmacology model for the development and optimization of mRNA vaccines.
Friday 9:15-9:35 |
D-03 Erwin Dreesen
A patient stratification tool for selecting tuberculosis treatment regimen composition and duration
Friday 9:35-9:55 |
D-04 Carlos Olivares
Mathematical Modeling Of Gut Microbiota Diversity Under The Effects of Beta-lactam Antibiotics
Friday 9:55-10:15 |
D-05
Preview of PAGE 2025
Friday 10:15-10:20 |
D-06
Coffee Break
Friday 10:20-11:05 |
D-08 Ruben Taieb
Mechanistic modelling of tumor kinetics coupled with biomarker dynamics for survival prediction in non-small cell lung cancer patients
Friday 11:05-11:25 |
D-09 Elisabeth Rouits
Incorporating clinical utility and Pharmacokinetics (PK)/Pharmacodynamics (PD) in clinical development of oncology drug candidate with a Bayesian decision analysis perspective in the context of OPTIMUS initiative
Friday 11:25-11:45 |
D-10
Closing Remarks
Friday 11:45-11:55 |
